TRENTON, NJ- New Jersey is part of a coalition of 50 states and territories seeking preliminary approval for a $39.1 million settlement with Apotex. The settlement addresses allegations of conspiracy to inflate prices and restrict competition for generic drugs.
Attorney General Matthew J. Platkin, along with a multistate coalition, initially announced the settlement with Apotex last fall, alongside a similar $10 million agreement with Heritage Pharmaceuticals. After securing necessary signatures, the coalition filed a motion for the settlement’s preliminary approval in the U.S. District Court for the District of Connecticut in Hartford.
Consumers who purchased certain generic prescription drugs from May 2009 to December 2019 may be eligible for compensation. To check eligibility, they can call a toll-free number, send an email, or visit the provided website.
Both Apotex and Heritage have agreed to cooperate with ongoing multistate litigation involving 30 corporate defendants and 25 individual executives. The companies will implement internal reforms to ensure compliance with antitrust laws, contributing to the resolution of past infractions and prevention of future misconduct.
